US Patent 11401512 Engineered target specific nucleases
Patent 11401512 was granted and assigned to Sangamo Therapeutics on August, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 16 Oct, 2023
Golden AI
Edits made to:
Infobox (+4 properties)
Infobox
Patent Inventor Names
Ivan Krivega0
Jeffrey C. Miller0
Lei Zhang0
Russell DeKelver0
Edits on 4 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
114015120
Date of Patent
August 2, 2022
0Patent Application Number
162712500
Date Filed
February 8, 2019
0Patent Citations
Patent Primary Examiner
CPC Code
Edits on 3 Aug, 2022
Golden AI
Edits made to:
Infobox (+12 properties)
Article (+237 characters)
US Patent 11401512 Engineered target specific nucleases
Article
Described herein are engineered nucleases comprising mutations in the cleavage domain (e.g., FokI or homologue thereof) and/or DNA binding domain (zinc finger protein, TALE, single guide RNA) such that on-target specificity is increased.
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11401512
Date of patent
August 2, 2022
Patent application number
16271250
Date Filed
February 8, 2019
Patent primary examiner
CPC Code
Find more entities like US Patent 11401512 Engineered target specific nucleases
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
